19048-76-1

Upstream product

• 16766-30-6 4-Chloroguaiacol 
• 105-36-2 ethyl bromoacetate 

Downstream Products

• 6738-03-0 N,N-Diethyl-N'-<(4-chlor-2-methoxy-phenoxy)-acetyl>-ethylendiamin 
• 7417-89-2 4-chloro-2-hydroxy phenoxyacetic acid 
• 847148-12-3 [4-chloro-2-[4-(ethylsulfonyl)phenoxy]phenoxy]-acetic acid sodium salt 
• 847148-43-0 {4-chloro-2-[4-(methylsulfonyl)phenoxy]phenoxy}acetic acid sodium salt 
• 847149-17-1 methyl {4-chloro-2-[4-(methylsulfonyl)-3-(trifluoromethyl)phenoxy]phenoxy}acetate 
• 847149-16-0 {4-chloro-2-[4-(methylsulfonyl)-3-(trifluoromethyl)phenoxy]phenoxy}acetic acid 
• 847149-05-7 [4-chloro-2-(pyrimidin-5-yloxy)phenoxy]acetic acid 
• 946137-32-2 (2-hydroxy-4-chlorophenoxy)-N-ethylacetamide 

Relevant academic research and scientific papers

Mechanism-based thrombin inhibitors: Design, synthesis, and molecular docking of a new selective 2-oxo-2H-1-benzopyran derivative

New 2-oxo-2H-1-benzopyran derivatives were prepared to optimize 2a,b, initially developed as mechanism-based α-chymotrypsin (α-CT) inhibitors, into potent and selective thrombin (THR) inhibitors. From this study, 22, characterized by a 2-(N-ethyl-2′-oxoacetamide)-5′- chlorophenyl ester side chain, was shown to be a good THR inhibitor (k i/KI = 3455 M-1·s-1), displaying an excellent selectivity profile against other serine proteases such as factor Xa, trypsin, and α-CT. Docking analysis of this compound into the different protein structures revealed the molecular basis responsible for its potency and selectivity.

PHENOXIACETIC ACID DERIVATIVES

The invention relates to certain 2-substituted phenoxyacetic acid derivatives of formula (I), in which the variables are as defined in the claims, useful in the treatment of diseases or conditions in which modulation of the CRTh2 receptor is beneficial, s